Systematic Literature Review of the Efficacy of Available Interventions for Patients with Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) Who Have Previously Been Treated with ≥2 Lines of Tyrosine Kinase Inhibitors (TKIs)

被引：0

作者：

Atallah, Ehab ^{[1
]}

Patwardhan, Pallavi ^{[2
]}

Mojebi, Ali ^{[3
]}

Maegawa, Rodrigo ^{[2
]}

Wu, Ping ^{[3
]}

Thakur, Deepika ^{[4
]}

Keeping, Sam ^{[3
]}

Viana, Ricardo ^{[5
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] Novartis Pharmaceut, E Hanover, NJ USA

[3] PRECISIONheor, New York, NY USA

[4] Novartis Healthcare Pvt Ltd, Chennai, Tamil Nadu, India

[5] Novartis Pharma AG, Basel, Switzerland

来源：

关键词：

chronic myeloid leukemia; chronic myelogenous leukemia; tyrosine kinase inhibitor; systematic review; literature review;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-246

引用

页码：S238 / S239

页数：2